Save on Lumizyme with Coupons, Discounts & Savings Programs

Lumizyme is the brand name for alglucosidase alfa IV infusion.

Lumizyme is available as a 5 mg/mL solution.

Lumizyme is an enzyme replacement therapy used to treat Pompe disease.

Lumizyme is an enzyme replacement therapy. It replaces an enzyme (protein) that helps the body break down a large sugar called glycogen. People with Pompe disease aren’t able to break down glycogen because they’re either missing that enzyme or the enzyme doesn’t work. So glycogen can build up in the body and cause problems, especially in the muscles. Lumizyme replaces the enzyme, which allows the body to break down glycogen and use it for energy.

The recommended dosage of Lumizyme is 20 mg/kg body weight administered every 2 weeks as an intravenous infusion.

Lumizyme is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Lumizyme:

• Infants:
• Rash
• Fever
• Hives
• Flushing
• Cough
• Fast breathing
• Fast heart rate
• Children and adults:
• Excessive sweating
• Hives
• Chest discomfort
• Muscle twitching

Serious side effects are rare with Lumizyme. Contact your healthcare provider immediately if you experience any of the following.

• Serious allergic and skin reactions: hives, rash, blisters, skin reddening, swelling of the lips or tongue, difficulty breathing

• There are no major drug interactions listed for Lumizyme. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking

sanofi-aventis U.S.

It is not known if Lumizyme will harm your unborn baby. Tell your healthcare provider if you become pregnant while taking Lumizyme. Patients and their caregivers should be informed that a registry for patients with Pompe disease (the Pompe Registry) has been established in order to better understand the variability and progression of Pompe disease, and to continue to monitor and evaluate long-term treatment effects of Lumizyme. The Pompe Registry will also monitor the effect of Lumizyme on pregnant women and their offspring [see Use in Specific Populations (8)]. Patients and their caregivers are encouraged to participate in the Pompe Registry and advised that their participation is voluntary and may involve long-term follow-up. For more information regarding the registry program call 1-800-745-4447.

• Alglucosidase Alfa